Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.

Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.
复制标题

DOI:
10.1007/s11912-020-0888-x
复制
发表时间:
2020-02-12
影响因子:
4.7
通讯作者:
Matsuo K
Matsuo K
中科院分区:
医学2区
文献类型:
--
作者:
Matsuzaki S;Klar M;Mikami M;Shimada M;Grubbs BH;Fujiwara K;Roman LD;Matsuo K

文献摘要

参考文献

被引文献

相似文献

回顾和讨论目前基于手术和放射治疗的IIB期宫颈癌治疗策略的证据。最近,两个随机对照试验比较了新辅助化疗加根治性子宫切除术(NACT+RH)和同期放化疗(CCRT)治疗IB3-IIB期宫颈癌的疗效。当这些研究结合在一起时(N=1259),NACT+RH与CCRT的结果相比,无病生存期较短[风险比(HR)1.36,95%可信区间(CI)1.13~1.64],但总体生存率相似(HR 1.11,95%CI 0.90~1.36)。对IIB期宫颈癌的分期分析显示,NACT+RH组的无瘤生存率显著低于CCRT组(HR 1.90,95%CI 1.25~2.89),而IB3-IIA期宫颈癌的无瘤生存率无显著差异。根据最近I级证据的结果,IIB期宫颈癌的标准治疗方法仍然是CCRT。
To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer. Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (N = 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer. Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.
DOI: 10.1016/j.ejca.2008.10.026
发表时间: 2009-01-01
影响因子: 8.4
作者:
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者: Verweij, J.
DOI: 10.1038/sj.bjc.6601157
发表时间: 2003-09-01
影响因子: 8.8
作者:
通讯作者: --
DOI: 10.1007/s00428-018-2362-9
发表时间: 2018-06-01
期刊: VIRCHOWS ARCHIV
影响因子: 3.5
作者:
Cibula, David;Poetter, Richard;Raspollini, Maria Rosaria
通讯作者: Raspollini, Maria Rosaria
根治性子宫切除术联合辅助放疗与根治性放疗治疗FIGO IIB期宫颈癌的比较
DOI: 10.1186/1471-2407-14-63
发表时间: 2014-02-04
期刊: BMC cancer
影响因子: 3.8
作者:
Chai Y;Wang T;Wang J;Yang Y;Gao Y;Gao J;Gao S;Wang Y;Zhou X;Liu Z
通讯作者: Liu Z
DOI: 10.1016/j.ygyno.2008.05.026
发表时间: 2008-09-01
影响因子: 4.7
作者:
Chen, Huijun;Liang, Chuan;Wu, Xufeng
通讯作者: Wu, Xufeng